PPH
VanEck Pharmaceutical ETF
MVIS US Listed Pharmaceutical 25 NR USD
NAV as of
4 Week: 75.83 - 79.54
52 Week: 66.73 - 80.55
Latest Closing Price
75.83
Premium / Discount
-0.03
Expense Ratio
0.36%
Investment Objective
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -2.46 | 0.74 | -3.30 |
| 1 Day | -0.21 | 0.00 | 0.00 |
| 1 Week | -3.35 | 1.16 | -2.90 |
| 1 Month | -3.20 | 2.67 | -1.20 |
| 3 Months | -1.11 | 5.96 | -0.19 |
| 6 Months | -0.20 | 8.45 | -0.02 |
| 1 Year | -4.86 | 15.37 | -0.32 |
| 2 Years | 4.64 | 20.83 | 0.22 |
| 3 Years | 23.36 | 26.27 | 0.89 |
| 5 Years | 29.98 | 41.60 | 0.72 |
| 10 Years | 59.68 | 54.00 | 1.11 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 36.8282 | 23.0764 | 3.4122 | -17.7644 | 15.3704 | -5.5239 | 19.0112 | 5.3801 | 17.8079 | 2.6617 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 89.0000 | 80.0000 | 89.0000 | 86.0000 | 84.0000 | 77.0000 | 84.0000 | 99.0000 | 25.0000 | 3.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| 02/04/2023 | 09/04/2023 | 0.6641 |
| 27/12/2022 | 29/12/2022 | 0.2400 |
| 02/10/2022 | 06/10/2022 | 0.2696 |
| 30/06/2022 | 07/07/2022 | 0.2496 |
| 31/03/2022 | 06/04/2022 | 0.4429 |
| 28/12/2021 | 30/12/2021 | 0.2691 |
| 30/09/2021 | 06/10/2021 | 0.3453 |
| 30/06/2021 | 07/07/2021 | 0.2859 |
| 31/03/2021 | 07/04/2021 | 0.3497 |
| 28/12/2020 | 04/01/2021 | 0.2662 |
Portfolio Data
Total Number of Holdings: 25
Number of Bond Holdings: 0
Number of Equity Holdings: 25
Total Market Value: 405,378,306
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | AbbVie Inc | 5.7093 | 126,652 | 0 | 10,353,801 |
| 2 | AstraZeneca PLC ADR | 5.4486 | 204,199 | 0 | 9,881,190 |
| 3 | Novo Nordisk A/S ADR | 5.3894 | 173,109 | 0 | 9,773,734 |
| 4 | GlaxoSmithKline PLC ADR | 5.3823 | 215,615 | 0 | 9,760,891 |
| 5 | Sanofi SA ADR | 5.0883 | 202,183 | 0 | 9,227,632 |
| 6 | Bristol-Myers Squibb Company | 5.0703 | 160,866 | 0 | 9,195,101 |
| 7 | Pfizer Inc | 4.9801 | 235,256 | 0 | 9,031,478 |
| 8 | Merck & Co Inc | 4.9714 | 106,141 | 0 | 9,015,617 |
| 9 | Eli Lilly and Co | 4.8888 | 78,801 | 0 | 8,865,901 |
| 10 | Johnson & Johnson | 4.8538 | 67,092 | 0 | 8,802,470 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 57.36 |
| Large | 23.33 |
| Medium | 15.26 |
| Small | 4.05 |
| Micro | 0.00 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
12.1655
Price/Book*
2.8033
Price/Sales*
0.9372
Price/Cash Flow*
10.6781
Dividend Yield*
2.4568
Growth Measures
Long-Term Earnings
8.4173
Historical Earnings
11.6189
Sales Growth
6.9970
Cash-Flow Growth
-3.5219
Book-Value Growth
-0.0217
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
